The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRγ through AKT and ERK1/2

European Journal of Cancer Prevention

Volumn 23, Issue 5, 2014, Pages 418-424

  Sun, Yan ^a   Wang, Cuicui ^a   Yang, Hui ^a   Ma, Xiaoxin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

endometrial cancer cells; estrogen; estrogen related receptor ; proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RELATED RECEPTOR GAMMA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ESRRG PROTEIN, HUMAN; ESTROGEN; MAPK1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA;

ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESTROGEN ACTIVITY; FEMALE; GENE SILENCING; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MTT ASSAY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE TRANSFECTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84905215883     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000052     Document Type: Article

References (18)

1. Ariazi EA, Jordan VC (2006). Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem 6:203-215.
2. Berstein L, Tchernobrovkina A, Gamajunova V, Kovalevskij AJ, Vasilyev DA, Chepik OF, et al. (2003). Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Onc 129:245-249.
3. Brinkkoetter PT, Olivier P, Wu JS, Henderson S, Krofft RD, Pippin JW, et al. (2009). Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J Clin Invest 119:3089-3101.
4. Burns KA, Korach KS (2012). Estrogen receptors and human disease: an update. Arch Toxicol 86:1491-1504.
5. Caringella AM, Di Naro E, Loverro G (2011). Clinical function of estrogen receptors in endometrial cancer. Minerva Ginecol 63:495-504.
6. Dixon KM, Lui GY, Kovacevic Z, Zhang D, Yao M, Chen Z, et al. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br J Cancer 108:409-419.
7. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. (2008). Novel molecular profiles of endometrial cancer - new light through old windows. J Steroid Biochem Mol Biol 108:221-229.
8. Fresno A, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M (2004). PI3K/AKT signaling pathway and cancer. Cancer Treat Rev 30:193-204.
9. Gao M, Wei LH, Sun PM, Zhao D, Wang JL, Wang ZQ, Zhao C (2005). Expression of estrogen receptor-related receptor isoforms in endometrial carcinoma tissues and its clinical significance. Zhonghua Fu Chan Ke Za Zhi 40:756-760.
10. Giguère V (2002). To ERR in the estrogen pathway. Trends Endocrinol Metab 13:220-225.
11. Le J, Xie X, Feng YJ (2005). Obstetrics and gynecology. Beijing: People's Health Publishing House. pp. 298-300.
12. Poidatz D, Dos Santos E, Brulé A, De Mazancourt P, Dieudonné MN (2012). Estrogen-related receptor gamma modulates energy metabolism target genes in human trophoblast. Placenta 33:688-695.
13. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M (2013). Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 39:935-946.
14. Shu J, Fang S, Teichman PG, Xing L, Huang H (2012). Endometrial carcinoma tumorigenesis and pharmacotherapy research. Minerva Endocrinol 37:117-132.
15. Song Y, Dai F, Zhai D, Dong Y, Zhang J, Lu B, et al. (2012). Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis 15:421-432.
16. Sun P, Sehouli J, Denkert C, Mustea A, Könsgen D, Koch I, et al. (2005). Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med (Berl) 83:457-467.
17. Sun P, Wei L, Denkert C, Lichtenegger W, Sehouli J (2006). The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer. Anticancer Res 6 (2C):1699-1706.
18. Yamamoto T, Mori T, Sawada M, Kuroboshi H, Tatsumi H, Yoshioka T, et al. (2012). Estrogen-related receptor-γ regulates estrogen receptor-α responsiveness in uterine endometrial cancer. Int J Gynecol Cancer 22:1509-1516.